PE20130377A1 - Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion - Google Patents
Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacionInfo
- Publication number
- PE20130377A1 PE20130377A1 PE2012002519A PE2012002519A PE20130377A1 PE 20130377 A1 PE20130377 A1 PE 20130377A1 PE 2012002519 A PE2012002519 A PE 2012002519A PE 2012002519 A PE2012002519 A PE 2012002519A PE 20130377 A1 PE20130377 A1 PE 20130377A1
- Authority
- PE
- Peru
- Prior art keywords
- staurosporin
- benzoyl
- preparation
- crystalline form
- procedure
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Extraction Or Liquid Replacement (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
SE REFIERE A LA FORMA CRISTALINA II DE N-BENZOIL-ESTAUROSPORINA QUE PRESENTA UN PATRON DE DIFRACCION DE RAYOS X CON PICOS DE DIFRACCION A ANGULOS 2-TETA DE 3.4 ± 0.2, 6.0 ± 0.2, 7.8 ± 0.2, 8.7 ± 0.2, 9.2 ± 0.2, 9.7 ± 0.2, 10.1 ± 0.2, 10.4 ± 0.2, 11.2 ± 0.2, 12.6 ± 0.2, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCESO DE PREPARACION DE DICHA FORMA CRISTALINA QUE COMPRENDE: A) PROPORCIONAR UNA SOLUCION DE N-BENZOIL-ESTAUROSPORINA EN UN SOLVENTE TAL COMO ALCOHOL BENCILICO; B) PONER EN CONTACTO LA SOLUCION CON UN SEGUNDO SOLVENTE TAL COMO ETANOL O ETANOL EN AGUA PARA FORMAR UN PRECIPITADO; Y C) AISLAR EL PRECIPITADO
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62534304P | 2004-11-05 | 2004-11-05 | |
US64213105P | 2005-01-07 | 2005-01-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20130377A1 true PE20130377A1 (es) | 2013-04-03 |
Family
ID=35501294
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2009000199A PE20090433A1 (es) | 2004-11-05 | 2005-11-04 | Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion |
PE2012002519A PE20130377A1 (es) | 2004-11-05 | 2005-11-04 | Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion |
PE2005001297A PE20060947A1 (es) | 2004-11-05 | 2005-11-04 | Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2009000199A PE20090433A1 (es) | 2004-11-05 | 2005-11-04 | Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2005001297A PE20060947A1 (es) | 2004-11-05 | 2005-11-04 | Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion |
Country Status (31)
Country | Link |
---|---|
US (2) | US8198435B2 (es) |
EP (3) | EP2955186A1 (es) |
JP (4) | JP5057986B2 (es) |
KR (3) | KR101333851B1 (es) |
CN (2) | CN102993213A (es) |
AR (1) | AR052322A1 (es) |
AU (2) | AU2005300693B2 (es) |
BR (1) | BRPI0517689A (es) |
CA (1) | CA2584911C (es) |
CY (1) | CY1113059T1 (es) |
DK (1) | DK1812448T3 (es) |
EC (1) | ECSP12007431A (es) |
ES (1) | ES2388142T3 (es) |
GT (1) | GT200500311A (es) |
HK (2) | HK1211587A1 (es) |
HR (1) | HRP20120652T1 (es) |
IL (3) | IL182691A (es) |
JO (1) | JO2897B1 (es) |
MA (1) | MA29033B1 (es) |
MX (2) | MX346525B (es) |
MY (2) | MY154878A (es) |
NO (2) | NO338960B1 (es) |
NZ (3) | NZ599033A (es) |
PE (3) | PE20090433A1 (es) |
PL (1) | PL1812448T3 (es) |
PT (1) | PT1812448E (es) |
RU (2) | RU2394038C2 (es) |
SI (1) | SI1812448T1 (es) |
TN (1) | TNSN07165A1 (es) |
TW (4) | TWI433852B (es) |
WO (1) | WO2006048296A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101462693B1 (ko) * | 2006-08-16 | 2014-11-17 | 노파르티스 아게 | 고도 결정질 치료용 화합물의 고체 분산체 제조 방법 |
EP2327706A1 (en) * | 2009-11-30 | 2011-06-01 | Novartis AG | Polymorphous forms III and IV of N-benzoyl-staurosporine |
KR20160008267A (ko) | 2014-07-14 | 2016-01-22 | 주식회사 윈스 | 네트워크 기반 영상감시체계에서의 사용자 행위 분석 시스템 |
EP3592749A1 (en) * | 2017-03-06 | 2020-01-15 | Teva Pharmaceutical Works Ltd. | Solid state forms of midostaurin |
WO2019215759A1 (en) * | 2018-05-09 | 2019-11-14 | Alaparthi Lakshmi Prasad | An improved process for preparation of midostaurin |
IT201900004729A1 (it) | 2019-03-29 | 2020-09-29 | Procos Spa | Processo per la preparazione di midostaurina ad elevato grado di purezza |
US20220242880A1 (en) * | 2019-06-24 | 2022-08-04 | Dr. Reddy?s Laboratories Limited | Process for preparation of midostaurin |
IT201900014346A1 (it) | 2019-08-08 | 2021-02-08 | Procos Spa | Processo per la preparazione di midostaurina amorfa con un basso contenuto di solvente organico residuo |
IT202000004291A1 (it) | 2020-03-02 | 2021-09-02 | Indena Spa | Processo per la purificazione di alcaloidi indolo carbazolici |
CN111393454A (zh) * | 2020-05-07 | 2020-07-10 | 奥锐特药业(天津)有限公司 | 米哚妥林的新晶型及其制备方法 |
CN115124551B (zh) * | 2021-03-24 | 2024-04-30 | 奥锐特药业(天津)有限公司 | 一种高纯度米哚妥林的制备方法 |
WO2023205504A1 (en) * | 2022-04-22 | 2023-10-26 | Rutgers, The State University Of New Jersey | Formulations and methods for treating epidermolysis bullosa simplex and related conditions |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5373501A (en) * | 1976-12-11 | 1978-06-30 | Kitasato Inst | Novel antibiotics amm2282 and process for preparing same |
JPS60185719A (ja) | 1984-03-06 | 1985-09-21 | Ajinomoto Co Inc | 抗腫瘍剤 |
US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
IL86632A0 (en) * | 1987-06-15 | 1988-11-30 | Ciba Geigy Ag | Derivatives substituted at methyl-amino nitrogen |
US5073633A (en) * | 1989-03-23 | 1991-12-17 | Bristol-Myers Company | BMY-41950 antitumor antibiotic |
US5096330A (en) * | 1990-06-21 | 1992-03-17 | M-B-W Inc. | Pitch control mechanism for a surface finishing machine |
JPH05247055A (ja) * | 1992-03-03 | 1993-09-24 | Meiji Seika Kaisha Ltd | スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤 |
JPH05247955A (ja) | 1992-03-06 | 1993-09-24 | Taisei Corp | 擁壁の施工方法 |
ES2136103T3 (es) | 1992-06-22 | 1999-11-16 | Kyowa Hakko Kogyo Kk | Procedimiento para la preparacion de derivados de estaurosporina. |
WO1995032975A1 (en) * | 1994-06-01 | 1995-12-07 | Ciba-Geigy Ag | Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents |
RU2191175C2 (ru) | 1995-12-11 | 2002-10-20 | Сефалон, Инкорпорейтед | Конденсированные изоиндолоны в качестве ингибиторов протеинкиназы с |
US6878804B1 (en) | 1999-08-30 | 2005-04-12 | University Of Zurich | Synthesis of template-fixed β-hairpin loop mimetics |
PT1372611E (pt) | 2001-03-26 | 2006-08-31 | Novartis Ag | Composicao farmaceutica compreendendo uma estaurosporina francamente soluvel em agua, um tensioactivo et um polimero soluvel em agua |
KR100407758B1 (ko) | 2001-08-27 | 2003-12-01 | 씨제이 주식회사 | 스타틴의 제조에 있어서 락톤화 방법 |
US7608420B2 (en) * | 2003-04-22 | 2009-10-27 | Lonza Ag | Process for the recovery of staurosporine from a fermentation broth |
-
2005
- 2005-10-26 JO JO2005162A patent/JO2897B1/en active
- 2005-10-28 GT GT200500311A patent/GT200500311A/es unknown
- 2005-10-28 MY MYPI20091911A patent/MY154878A/en unknown
- 2005-10-28 MY MYPI20055091A patent/MY147404A/en unknown
- 2005-11-03 EP EP15171908.5A patent/EP2955186A1/en not_active Withdrawn
- 2005-11-03 MX MX2011007303A patent/MX346525B/es unknown
- 2005-11-03 KR KR1020077010191A patent/KR101333851B1/ko active IP Right Grant
- 2005-11-03 PL PL05803350T patent/PL1812448T3/pl unknown
- 2005-11-03 BR BRPI0517689-1A patent/BRPI0517689A/pt not_active IP Right Cessation
- 2005-11-03 NZ NZ599033A patent/NZ599033A/xx not_active IP Right Cessation
- 2005-11-03 EP EP10173464.8A patent/EP2272850B1/en active Active
- 2005-11-03 KR KR1020127022584A patent/KR101289998B1/ko active IP Right Grant
- 2005-11-03 ES ES05803350T patent/ES2388142T3/es active Active
- 2005-11-03 EP EP05803350A patent/EP1812448B1/en active Active
- 2005-11-03 AU AU2005300693A patent/AU2005300693B2/en active Active
- 2005-11-03 MX MX2007005429A patent/MX2007005429A/es active IP Right Grant
- 2005-11-03 US US11/718,029 patent/US8198435B2/en active Active
- 2005-11-03 WO PCT/EP2005/011789 patent/WO2006048296A1/en active Application Filing
- 2005-11-03 RU RU2007120695/04A patent/RU2394038C2/ru active
- 2005-11-03 JP JP2007539535A patent/JP5057986B2/ja active Active
- 2005-11-03 PT PT05803350T patent/PT1812448E/pt unknown
- 2005-11-03 CN CN2012104320940A patent/CN102993213A/zh active Pending
- 2005-11-03 SI SI200531555T patent/SI1812448T1/sl unknown
- 2005-11-03 CA CA2584911A patent/CA2584911C/en active Active
- 2005-11-03 CN CN2012101018747A patent/CN102627658A/zh active Pending
- 2005-11-03 DK DK05803350.7T patent/DK1812448T3/da active
- 2005-11-03 NZ NZ588025A patent/NZ588025A/en not_active IP Right Cessation
- 2005-11-03 KR KR1020127022582A patent/KR101265850B1/ko active IP Right Grant
- 2005-11-03 NZ NZ554653A patent/NZ554653A/en not_active IP Right Cessation
- 2005-11-04 TW TW094138677A patent/TWI433852B/zh not_active IP Right Cessation
- 2005-11-04 TW TW103130302A patent/TWI530501B/zh not_active IP Right Cessation
- 2005-11-04 AR ARP050104637A patent/AR052322A1/es not_active Application Discontinuation
- 2005-11-04 TW TW101122880A patent/TWI530500B/zh not_active IP Right Cessation
- 2005-11-04 PE PE2009000199A patent/PE20090433A1/es not_active Application Discontinuation
- 2005-11-04 PE PE2012002519A patent/PE20130377A1/es not_active Application Discontinuation
- 2005-11-04 TW TW101122882A patent/TWI455941B/zh not_active IP Right Cessation
- 2005-11-04 PE PE2005001297A patent/PE20060947A1/es not_active Application Discontinuation
-
2007
- 2007-04-19 IL IL182691A patent/IL182691A/en active IP Right Grant
- 2007-05-02 NO NO20072290A patent/NO338960B1/no unknown
- 2007-05-04 TN TNP2007000165A patent/TNSN07165A1/fr unknown
- 2007-05-22 MA MA29924A patent/MA29033B1/fr unknown
- 2007-12-19 HK HK15112508.3A patent/HK1211587A1/xx unknown
- 2007-12-19 HK HK07113889.0A patent/HK1108881A1/xx unknown
-
2009
- 2009-10-13 RU RU2009137788/04A patent/RU2467012C2/ru active
- 2009-12-07 AU AU2009245817A patent/AU2009245817B2/en active Active
-
2010
- 2010-08-19 IL IL207702A patent/IL207702A/en active IP Right Grant
-
2012
- 2012-01-16 IL IL217571A patent/IL217571A/en active IP Right Grant
- 2012-03-12 EC ECSP12007431 patent/ECSP12007431A/es unknown
- 2012-05-11 JP JP2012109447A patent/JP5701246B2/ja active Active
- 2012-05-15 US US13/472,130 patent/US8710216B2/en active Active
- 2012-08-10 HR HRP20120652TT patent/HRP20120652T1/hr unknown
- 2012-08-21 CY CY20121100747T patent/CY1113059T1/el unknown
-
2015
- 2015-01-09 JP JP2015003634A patent/JP2015063569A/ja not_active Withdrawn
-
2016
- 2016-07-12 NO NO20161152A patent/NO340404B1/no unknown
-
2017
- 2017-01-13 JP JP2017004320A patent/JP2017061578A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20130377A1 (es) | Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion | |
ES2620442T3 (es) | Uso de derivados de tetraquis(N-alquilpiridinio)-porfirina para la destrucción de microbios o la prevención de su crecimiento | |
UY27720A1 (es) | Aroilpiridinonas monocíclicas, | |
AR055552A1 (es) | Preparacion topica refrescante para parches y metodos para utilizar la misma | |
BRPI0510231A (pt) | composto, polimorfo cristalino, cossolvato em metanol e água, cossolvato em metanol-água, cossolvato em etanol-água, composição farmacêutica, método para administrar um agente ativo, método para preparar a forma i do snac, método para preparar a forma ii de snac, método para preparar a forma iii de snac, método para preparar a forma iv de snac, método para preparar a forma v de snac, método para preparar a forma vi de snac, composição farmacêutica e método para preparar snac amorfo | |
AR056055A1 (es) | Complejos cristalinos e hidratos de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-etinil-bencil)-benceno | |
CL2007001918A1 (es) | Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras. | |
BRPI0719849A2 (pt) | Método de imunização contra os quatro sorotipos da dengue | |
CL2007003187A1 (es) | Compuestos derivados de bencil-benzonitrilo sustituido con glucopiranosilo y sus sales; procedimiento de preparacion; compuestos intermediarios; proceso para preparar los compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de | |
CL2007002207A1 (es) | Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma. | |
AR055761A1 (es) | Procedimiento para preparar especies de aluminio | |
ECSP10010303A (es) | (dihidro)pirrolo[2,1-a]isoquinolinas | |
CL2007003643A1 (es) | Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas. | |
NI200600146A (es) | Composición farmacéutica de vinflunina para administración parenteral, proceso de preparación y su uso | |
CL2008002082A1 (es) | Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades. | |
AR060264A1 (es) | Composicion farmaceutica que contiene lactato y calcio, usos de dicha composicion y metodo de preparacion | |
AR063792A1 (es) | Uso de copolimerizados de bloques a base de vinillactamas y acetato de vinilo como solubilizantes | |
ECSP099506A (es) | Derivados de 2-quinolinona y 2 quinoxalinona y su utilización como agentes anti bacterianos | |
PE20070548A1 (es) | Formas cristalinas de la sal de di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico | |
ECSP099596A (es) | Composición farmacéutica que contiene una combinación de tramadol y ketoprofeno | |
AR042712A1 (es) | Uso de inhibidores de quinurenina 3- hidroxilasa para el tratamiento de la diabetes por incremento de la cantidad de celulas de los islotes de langerhans | |
NO20040614L (no) | Preparater som inneholder konjugert linolalkohol. | |
CL2007000485A1 (es) | Sal de alisquereno; procedimiento de preparacion; composicion farmaceutica que comprende a dicha sal; y uso del compuesto para el tratamiento de enfermedades que puedan ser moduladas mediante la inhibicion de la renina. | |
CL2008002289A1 (es) | Compuestos derivados de n-heteroaril-carboxamidas triciclicas; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar dolor, inflamacion, trastornos metabolicos, trastornos urologicos, entre otros. | |
PE20130064A1 (es) | Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |